Trial Profile
BIO-SWITCH study: Biosimilar of Infliximab Options, Strengths and Weaknesses of Infliximab Treatment CHange
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 01 Aug 2021
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Ankylosing spondylitis; Psoriatic arthritis; Rheumatoid arthritis; Spondylarthritis
- Focus Therapeutic Use
- Acronyms BIO-SWITCH
- 18 Oct 2017 Status changed from recruiting to active, no longer recruiting as per the results published in the Arthritis and Rheumatology
- 18 Oct 2017 Results published in the Arthritis and Rheumatology
- 24 Aug 2015 New trial record